Skip to main content
Erschienen in: Seminars in Immunopathology 3/2018

Open Access 03.04.2018 | Review

A historical perspective on the role of sensory nerves in neurogenic inflammation

Erschienen in: Seminars in Immunopathology | Ausgabe 3/2018

Abstract

The term ‘neurogenic inflammation’ is commonly used, especially with respect to the role of sensory nerves within inflammatory disease. However, despite over a century of research, we remain unclear about the role of these nerves in the vascular biology of inflammation, as compared with their interacting role in pain processing and of their potential for therapeutic manipulation. This chapter attempts to discuss the progress in understanding, from the initial discovery of sensory nerves until the present day. This covers pioneering findings that these nerves exist, are involved in vascular events and act as important sensors of environmental changes, including injury and infection. This is followed by discovery of the contents they release such as the established vasoactive neuropeptides substance P and CGRP as well as anti-inflammatory peptides such as the opioids and somatostatin. The more recent emergence of the importance of the transient receptor potential (TRP) channels has revealed some of the mechanisms by which these nerves sense environmental stimuli. This knowledge enables a platform from which to learn of the potential role of neurogenic inflammation in disease and in turn of novel therapeutic targets.
Hinweise
This article is a contribution to the special issue on Neurogenic Inflammation -- Guest Editors: Tony Yaksh and Anna Di Nardo

Introduction

Early history

The term ‘neurogenic inflammation’ is commonly used to describe the concept that sensory nerves participate in inflammation. The neuropeptide-containing sensory nerves involving the cutaneous system are historically defined as primarily the thin slow conducting C-fibres (1.5–0.3 μm) which are unmyelinated and the small (6-11 μm) Aδ-fibres which possess a thin layer of myelin, predominantly forming part of the somatic nervous system [1]. The history of the development of our knowledge of neurogenic inflammation and of the sensory nerves is fascinating, but complex. The discovery pathway is not linear, with several scientists making similar discoveries around the world at the same time. Whilst some have become historically famous, others even though they made a seminal discovery are not. Goltz realised that the sciatic nerve of the dog contained vasodilator fibres, in addition to the normal constrictor nerves [2]. This was also observed by Stricker (1876) who provided evidence of how sensory nerves may contribute to inflammation [3]. He observed that dorsal roots of the dog when stimulated in an antidromic manner caused an increased blood flow in the skin of the area that was innervated by the sensory nerves, through the use of a mercury thermometer placed between the toes [3].
Meanwhile, Sherrington produced some key studies to show the connecting sensory cutaneous fields and their innervation by spinal afferents. He coined the phrase ‘sensory spinal skin-field’, to differentiate from motor spinal reflexes [4]. This finding was supported by Bayliss in 1901 and Langley (1923), with also a realisation by this time that these findings could be expanded to other species such as the cat and frog [5, 6]. Bayliss stated that the findings he described were of ‘rather a revolutionary nature’. It was these key studies and their discussions that led to the definitions of ‘antidromic vasodilation’, as the dorsal roots only have afferent fibres and removal of dorsal roots abolished the vasodilation (also known as neurogenic vasodilation). Thus, sensory nerves mediate vasodilation.
There were some complementary studies ongoing and several key people were working in this area at the time. The studies that revolved around herpes zoster and the resulting cutaneous pathology were brought into context recently by Oaklander [7]. Knowledge was lacking on the distribution in the skin of the afferent nerve fibres that travel from the skin to the dorsal roots of the spinal cord. Whilst many have since worked to link the sensory nerve system to inflammation in addition to pain, since this time, there was a vital observation before this between herpes zoster and the sensory nervous system. It is now established that varicella-zoster virus, a human herpes virus that causes chickenpox, can become latent in trigeminal and dorsal root ganglia, to be reactivated to mediate shingles (herpes zoster) [8]. A neurologist (Sir Henry Head) and pathologist (Campbell) joined together to write a large monograph where they identified herpes zoster as a disease of the nervous system, involving increased blood flow at the lesional site [9]. Sir Henry Head worked in humans with herpes zoster. He provided the foundation knowledge for dermatomes in his studies for his PhD (1893) and later through a monograph that is still widely referred to today [9]. They were aware of criticisms of their work from others, but concluded the location was in the sensory nerves and their dorsal roots and some were more likely to be affected than others. They also tried to understand the accompanying inflammation and degeneration and through this provided a remarkable recorded insight. The Head and Campbell manuscript is still considered classic within the virology field [7, 10]. This brought centre stage the concept that the sensory nerves play a pivotal role in inflammation, although at the time it does not appear to be acknowledged to any great extent by the classical physiologists. The importance of this work is that, not only was it detailed and thorough, but also it soon became impossible to do that type of work, as the science was allowed to go ahead, involving humans in a way that is impossible today. Critical to their detailed analysis, they were able to study people who had died at institutions (including Guy’s Hospital here at King’s), where they were recorded as previously suffering from herpes zoster. They compared locations of lesions and rash from the clinical notes with that of the nerves and ganglion that were found to innervate the patient at post mortem inspection.
These findings were confirmed and extended such that specific areas of the skin were associated with a certain spinal root and was defined as a dermatome, with little overlap, as determined by either anatomical or physiological methods. A remarkable review by Foerster in 1933 discusses how others (e.g. Herringham and Bolk) traced single roots by dissection to the skin [11]. The work was greatly enhanced by that of Sherrington who teased out nerves and defined the dermatomes in monkeys [4]. Their knowledge utilised the vasodilator properties of sensory nerves as defined by Stricker and Bayliss from animal studies [3, 6]. Foerster concluded from his very complete and very visual studies, from 30 years of work as a neurologist, that areas of vasodilation produced by electrical stimulation of posterior roots are similar, but not identical, to anatomical localisation, and relate to the eruption of herpes in that area. Moreover, in terms of nociception, and taking the work of physiologists who were also able to work on animal species, the dermatome area is remarkedly represented by each filament in the root, so if only a few are lost, this has no effect. Post-herpatic pain was difficult, by comparison, to define. Specifically whether the pain was generalised or generated via the central or peripheral nervous system. At a time when the incidence of shingles advances (with increased longevity) and the pain is intense, this remains very topical today [12]. The inflammation is usually relatively acute, but the mechanisms behind the post-hepatic pain that affects many sufferers are debilitating [13].

Relevance of capsaicin and related chemicals

The next important discovery was that the topical application of mustard oil, an irritant chemical, to the skin increases blood flow and inflammatory swelling. In a historical review by Gabor Jancsó et al. (2009), they state that the less well known Spiess realised in 1906 that mustard oil, extracted from mustard seeds, induced inflammation that he considered to be due to spinal reflexes [14, 15]. However, the work of Bruce is better known and he realised that inflammation and vasodilation in the eye in response to topical mustard oil were not observed when the eye was anaesthetised or the sensory nerves had degenerated and suggested the involvement of axon reflexes and, by definition, an intact sensory nerve supply [16]. This was substantiated in 1918 by Breslauer who realised that mustard oil required intact sensory nerves in the skin [17]. Sir Thomas Lewis played an important part in allowing the mechanisms of neurogenic inflammation to be further understood through his studies into responses to skin injury. He is perhaps best known for his description of this injury as a ‘triple response’. The three components of this response are a wheal, a flare and a local reddening response. This triple response is similar to that observed when histamine is injected into the skin. The wheal response is caused by oedema formation as a result from increased microvascular permeability. The local reddening and the flare are both consequences of increased blood flow. The flare is of particular interest as it arises from an initial stimulus, leading to an area of erythema that spreads further from the site of injection shown to be dependent on an intact nerve supply. The phrase ‘axon reflex’ was coined where an initial stimulus is able to activate nerves leading to a spread of activation, generally considered to be due to nerve collaterals and, in this case, leading to skin vasodilation over quite a large area. The flare was not observed when the sensory nerves had degenerated, providing further proof for the axon reflex theory [18]. An important component of the work by Bayliss and Lewis was their suggestion, not really realised until the later development of elegant histological techniques, that these sensory nerves were localised perivascularly. These nerve endings are ideally situated for the release of the potent vasodilators that they are now known to contain [19].
However, despite the early relevance and interest in neurogenic inflammation, studies on this subject were stunted. Only in the 1960s was there a re-emergence building on earlier findings using mustard oil. Jancso and coworkers [20, 21] undertook mechanistic studies to elucidate the mediators which may be involved in this response, and soon realised that neurogenic inflammation was not inhibited by classic autonomic antagonists. With this, Jancso also highlighted the importance of another related compound, capsaicin, an irritant found in chilli pepper extract, in studying sensory nerves. Capsaicin was shown to have dual roles, where (1) at low concentration, it dose-dependently causes neurogenic inflammation, yet (2) at repeated, higher concentration leads to sensory nerve desensitisation and loss of neurogenic inflammation response [20, 21]. Of note, historically, it would appear that Hӧgyes reported burning to the skin with an extract of paprika (that would contain capsaicin) as early as 1878 and apparently concluded that it acted via sensory nerves [1]. Soon, Jancso defined a range of chemicals which had the ability to activate sensory nerves. Perhaps, most importantly, Jancso was the first to show the selectivity of capsaicin for sensory nerves and the pivotal finding that capsaicin desensitisation was able to reduce pain sensitivity, but not mechanical sensitivity. His work contributed to an important early basic understanding of the links between sensory nerves and the skin. Still today, sensory denervation mediated by capsaicin or related compounds mediated is one of the most common methods to induce sensory depletion or desensitisation. In addition to the close links between sensory nerves and the skin, this depletion technique seemed to be specific for targeting small-fibre sensory nerves throughout the body [22]. Of note, the application of 8% capsaicin patches has been suggested to help the pain control of some patients, with minimal side effects [12, 23]. These findings were key in realising that transient receptor potential (TRP) channels are localised to sensory nerves.

Discovery of the sensory neuropeptide substance P

The discovery of the major neuropeptide substance P took place over several decades. First, Dale suggested that sensory nerves released a transmitter and in studying it realised with Gaddum that it was novel, as not inhibited by any of the then studied major studied mediators (e.g. acetylcholine and histamine). Dale in 1935 considered the sensory transmitters and concluded that transmitters would be released to cause the vasodilation and should be released both antidromically and orthodromically [24]. The ‘P’ referred to a ‘powder’ that they prepared as a purified standard preparation. Gaddum and Schild are considered to have started using the name substance P and von Euler was involved in the extraction from the gut and brain [25]. The peptide structure of substance P was published in 1971 by Susan Leeman [26]. It was realised that capsaicin treatment of the spinal cord depleted substance P [27, 28]. Soon, it was realised that substance P was found throughout the central and peripheral nervous systems, from the work of Hokfelt [29]. Lembeck and colleagues confirmed the importance of substance P in mediating neurogenic vasodilation and increased microvascular permeability [30] updating the Bayliss technique to the rat and counting drips of blood. This response was not observed after capsaicin pretreatment [31, 32] or later when available, in the presence of substance P antagonists [33]. In human skin, substance P has the ability to mediate a histamine-induced flare [34], as shown in Fig. 1.
The word ‘tachykinin’ was developed by Erspamer and the best known members of the family are substance P, neurokinin A and neurokinin B [35]. However, it took some time to gain an understanding of the receptor family through which substance P acts. It is now known that substance P acts in a vasoactive manner predominantly through the neurokinin NK1 receptor and that the NK2 receptor with preference for neurokinin A and the NK3 receptor with preference NK3 also exist [36]. A major problem in unravelling the biology was that the receptors are species selective, such that the first generation of antagonists was not human selective [36]. Eventually, non-peptide NK1 receptor antagonists were developed, with the aim of being new analgesics and anti-inflammatory agents. Whilst these agents were effective in pre-clinical studies involving animal models, they were not in humans. A range of clinical trials including for arthritis and migraine and depression has failed [37]. There is a discussion among tachykinin experts that the NK1 antagonists will benefit pruritus, if only we knew more about the sensory nerves involved. Of note, the clinically used substance P antagonist aprepitant is approved for the treatment of nausea and vomiting induced by chemotherapy and a recent small study has shown that aprepitant benefited refractory pruritus associated with malignancies, inferring the need for further study [38]. Indeed, it is suggested that in total, recent small-scale studies have shown benefit in 110 patients suffering from pruritus given an NK1 antagonist, with larger clinical trials now ongoing [39].

Discovery of the sensory neuropeptide calcitonin gene-related peptide

The 37 amino acid calcitonin gene-related peptide (CGRP) was discovered using molecular biology techniques, when it was realised that alternative RNA processing of the gene for calcitonin results in the generation of CGRP. CGRP can exist in two forms (α and β), both of which differ minimally in structure and across species. The β form is produced by a separate gene and historically considered to be found in the gut and brain but has been more recently found in vascular sources and they have very similar biological activities [19]. Rosenfeld and colleagues showed that the rat thyroid medulla failed to maintain calcitonin production, when serially transplanted, switching instead to producing GGRP, via the alternative splicing of the gene [3, 6, 40]. Human αCGRP was discovered (34) [33]. It was soon realised when antibodies were produced and immune-histochemical studies performed that whilst CGRP is found in the thyroid of ageing rats and in human carcinoma of the thyroid, it is localised throughout the peripheral and central nervous systems with substance P in sensory nerves [41, 42]. Moreover, CGRP is an extremely potent microvascular vasodilator in the cutaneous circulation [19, 43]. Indeed, it is a vasodilator in most vascular beds, especially also associated with the heart and trigeminal circulations [44]. Evidence that CGRP was involved in cerebral regulation led to the intense study continuing until the present day of its role in migraine [19, 45].
CGRP is now known to be a member of the CGRP family, alongside adrenomedullin and amylin. CGRP acts through the CGRP receptor complex [46, 47]. This complex requires co-localisation of the G-protein component calcitonin-like receptor (CLR) with a single transmembrane component known as receptor activity-modifying protein 1 (RAMP1), and an intracellular signalling component receptor component protein (RCP) [47].
Over the years, some looked by at Thomas Lewis’s work on the axon reflex flare, in an attempt to understand its pharmacological mechanisms. Their research was hindered by the fact that it is not observed to such an extent in typical laboratory species, reviewed by Chapman (1977). Chapman, who studied this phenomenon suggested that a peptide similar to a kinin, neurotensin or substance P is responsible for the vasodilator response [48]. It is now realised that CGRP is most likely the principal mediator. It was shown to mediate the capsaicin-induced flare in humans in studies involving aprepitant, the cyclo-oxygenase inhibitor indomethacin and the nitric oxide synthase inhibitor L-NMMA [49]. CGRP had been known to mediate the cutaneous vasodilation following a low stimulation of the saphenous nerve in the rat; however, substance P mediates the oedema formation in this model upon more intense stimulation in this model [50]. The ability of endogenous substance P to mediate oedema formation in humans is more difficult to ascertain, although exogenous substance P is certainly active as discussed.
The pathological role of CGRP has been sought via development of antagonists and antibodies. This has been driven by evidence that it plays a major role in migraine [45] and possibly other processes associated with pain and itch [19, 51, 52]. CGRP antibodies and antagonists are in late-phase clinical trials for migraine. They have not been extensively investigated in patients with either cardiovascular or skin conditions to date. Indeed, the human administration of CGRP antagonists and antibodies has revealed that this potent vasodilator does not influence cardiovascular regulation in the healthy human. On the other hand, a lack of endogenous CGRP release may enhance cardiovascular disease as shown in CGRP knockout mice [53] and by the finding that a long-acting CGRP agonist benefits cardiovascular dysfunction, including heart failure in the mouse, and CGRP administration is beneficial in human heart failure and other vascular diseases [19, 54, 55]. Thus, this peptide may be a double-edged sword in terms of human physiology and pathology.

Other neuropeptides

Whilst substance P and CGRP are the best known neuropeptides, a range of others is either synthesised or upregulated to be synthesised in disease. One of these somatostatin was also discovered [56] and later shown to be anti-inflammatory, but despite drug development projects, its role remains unclear [57]. The neuropeptides are primarily synthesised at the dorsal root as larger pro-peptides and then travel antidromically via the neurons to the nerve terminals where they are released as the peptide from vesicles [19]. One of the most interesting aspects is their plasticity in terms of gene regulation in response to injury.

Sensory nerve activation. TRP receptors

The sensory nerves are activated by a range of environmental and endogenous stimuli, including thermal, mechanical and chemical, and are critically involved in processing nociceptive information [58] whilst providing the neurogenic influence in cardiovascular regulation and inflammation. The acute effects, such as oedema formation and increased blood flow, are involved in the response of the skin or other organs to exposure to environmental irritants. The chronic effects have been more difficult to tease out with many indications of pro- and anti-inflammatory effects of sensory nerves suggested. Overall, we still lack understanding in this area.

Transient receptor potential channels

Research initiated by the study of capsaicin led to the realisation that the transient receptor potential vanilloid 1 (TRPV1) is a capsaicin agonist [59]. Moreover, whilst it is found on some non-neuronal tissues, TRPV1 is primarily localised to sensory nerves and mediates noxious heat and thermal hyperalgesia [5961].
TRP Ankyrin 1 (TRPA1) channels are found on about 60–75% of TRPV1-positive sensory nerves [62]. These two TRP channels are activated by distinct chemical agents, with TRPV1 mediating noxious heat and TRPA1 mediating cooler temperatures including noxious cold [63, 64], with effects closely linked to temperature-induced vascular changes [65]. There is evidence that both TRPV1 and TRPA1 have important roles in acute and chronic inflammation from knee joint models such as Freund’s complete adjuvant (CFA) [66, 67]. Many pre-clinical studies using laboratory species implicate TRPV1 in hyperalgesia and inflammatory pathways. In comparison, studies using the first generation of TRPV1 antagonists have been less successful as they induce hyperthermia alongside a risk of a lack of awareness of hot surfaces [68]. However, second-generation TRPV1 antagonists are now reported to be in clinical trials that lack this hyperthermia effect [69]. Currently, TRPA1 antagonists are under clinical trials and shown to be beneficial in phase 2 clinical trials for diabetic neuropathy [70]. There are also a myriad of other TRP channels now under investigation (see Fig 2). The TRP family is composed of 28 ligand-gated non-selective cation (e.g. Ca2+) ion channels that are composed of subfamilies with defined sensitivities to temperature, chemicals and pressure [58]. This subject is of direct relevance to the contents of this book.
In conclusion, whilst much progress has been made over the years, there is a realisation that we still have many discoveries to make, especially those that relate to the role of these nerves and their activating systems. We find a range of exciting discoveries throughout this book but also many questions that are still unanswered.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Ramaye A (2016) Chemical excitants of cutaneous pain. Perspectives in Basic & Applied Toxicology, ed. B. Ballantyne 13 31–41 Ramaye A (2016) Chemical excitants of cutaneous pain. Perspectives in Basic & Applied Toxicology, ed. B. Ballantyne 13 31–41
2.
Zurück zum Zitat Goltz F, Freusberg A (1874) Ueber gefässerweiternde Nerven. Pflüger, Archiv für die Gesammte Physiologie des Menschen und der Thiere 9(1) 174-197 Goltz F, Freusberg A (1874) Ueber gefässerweiternde Nerven. Pflüger, Archiv für die Gesammte Physiologie des Menschen und der Thiere 9(1) 174-197
3.
Zurück zum Zitat Stricker S (1876) Untersuchungen uber die Gefasserwurzeln des Ischiadicus. Sitzungsberichte der Kaiserlichen Akademie der Wissenschaften in Wien 3 173–185 Stricker S (1876) Untersuchungen uber die Gefasserwurzeln des Ischiadicus. Sitzungsberichte der Kaiserlichen Akademie der Wissenschaften in Wien 3 173–185
4.
Zurück zum Zitat Sherrington CS (1893) Experiments in examination of the peripheral distribution of the fibres of the posterior roots of some spinal nerves. Philos Trans R Soc Lond B 184:641–763CrossRef Sherrington CS (1893) Experiments in examination of the peripheral distribution of the fibres of the posterior roots of some spinal nerves. Philos Trans R Soc Lond B 184:641–763CrossRef
6.
Zurück zum Zitat Bayliss WM (1901) On the origin from the spinal cord of the vaso-dilator fibres of the hind-limb, and on the nature of these fibres. J Physiol 26(3–4):173–209CrossRefPubMedPubMedCentral Bayliss WM (1901) On the origin from the spinal cord of the vaso-dilator fibres of the hind-limb, and on the nature of these fibres. J Physiol 26(3–4):173–209CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Oaklander AL (1999) The pathology of shingles: Head and Campbell’s 1900 monograph. Arch Neurol 56(10):1292–1294CrossRefPubMed Oaklander AL (1999) The pathology of shingles: Head and Campbell’s 1900 monograph. Arch Neurol 56(10):1292–1294CrossRefPubMed
8.
Zurück zum Zitat Kennedy PG (2002) Varicella-zoster virus latency in human ganglia. Rev Med Virol 12(5):327–334CrossRefPubMed Kennedy PG (2002) Varicella-zoster virus latency in human ganglia. Rev Med Virol 12(5):327–334CrossRefPubMed
9.
Zurück zum Zitat Head H, Campbell AW (1900) The pathology of herpes zoster and its bearing on sensory localisation. Brain 23(3):353–362CrossRef Head H, Campbell AW (1900) The pathology of herpes zoster and its bearing on sensory localisation. Brain 23(3):353–362CrossRef
10.
Zurück zum Zitat Head H, Campbell AW, Kennedy PG (1997) The pathology of herpes zoster and its bearing on sensory localisation. Rev Med Virol 7(3):131–143CrossRefPubMed Head H, Campbell AW, Kennedy PG (1997) The pathology of herpes zoster and its bearing on sensory localisation. Rev Med Virol 7(3):131–143CrossRefPubMed
11.
12.
Zurück zum Zitat Johnson RW, Rice AS (2014) Clinical practice. Postherpetic neuralgia. N Engl J Med 371(16):1526–1533CrossRefPubMed Johnson RW, Rice AS (2014) Clinical practice. Postherpetic neuralgia. N Engl J Med 371(16):1526–1533CrossRefPubMed
13.
Zurück zum Zitat Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK (2014) Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother 15(1):61–71CrossRefPubMed Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK (2014) Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother 15(1):61–71CrossRefPubMed
14.
Zurück zum Zitat Spiess G, Die Bedeutung der Anästhesie in der Entzündungstherapie, JF Lehmann1906 Spiess G, Die Bedeutung der Anästhesie in der Entzündungstherapie, JF Lehmann1906
15.
Zurück zum Zitat Jancsó G, Horváth V, Sántha P, Nagy J (2009) Sensory nerves as modulators of cutaneous inflammatory reactions in health and disease. Neuroimmune Biol 8:1–36CrossRef Jancsó G, Horváth V, Sántha P, Nagy J (2009) Sensory nerves as modulators of cutaneous inflammatory reactions in health and disease. Neuroimmune Biol 8:1–36CrossRef
16.
Zurück zum Zitat Bruce AN (1913) Vaso-dilator axon-reflexes. Q J Exp Physiol 6:339–354CrossRef Bruce AN (1913) Vaso-dilator axon-reflexes. Q J Exp Physiol 6:339–354CrossRef
17.
Zurück zum Zitat Breslauer F (1919) Die Pathogenese der trophischen Gewebsschäden nach der Nervenverletzung. Deutsche Zeitschrift für Chirurgie 150(1–2):50–81CrossRef Breslauer F (1919) Die Pathogenese der trophischen Gewebsschäden nach der Nervenverletzung. Deutsche Zeitschrift für Chirurgie 150(1–2):50–81CrossRef
18.
Zurück zum Zitat Lewis T (1924) Vascular reactions of the skin to injury. Part 1. Reaction to stroking; urticaria factitia. Heart 11:119–140 Lewis T (1924) Vascular reactions of the skin to injury. Part 1. Reaction to stroking; urticaria factitia. Heart 11:119–140
19.
Zurück zum Zitat Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142CrossRefPubMedPubMedCentral Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Jancso G, Kiraly E, Jancso-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 270(5639):741–743CrossRefPubMed Jancso G, Kiraly E, Jancso-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 270(5639):741–743CrossRefPubMed
21.
Zurück zum Zitat Jancso N, Jancso-Gabor A, Szolcsanyi J (1967) Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 31(1):138–151CrossRefPubMedPubMedCentral Jancso N, Jancso-Gabor A, Szolcsanyi J (1967) Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 31(1):138–151CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kun J, Szitter I, Kemeny A, Perkecz A, Kereskai L, Pohoczky K, Vincze A, Godi S, Szabo I, Szolcsanyi J, Pinter E, Helyes Z (2014) Upregulation of the transient receptor potential ankyrin 1 ion channel in the inflamed human and mouse colon and its protective roles. PLoS One 9(9):e108164CrossRefPubMedPubMedCentral Kun J, Szitter I, Kemeny A, Perkecz A, Kereskai L, Pohoczky K, Vincze A, Godi S, Szabo I, Szolcsanyi J, Pinter E, Helyes Z (2014) Upregulation of the transient receptor potential ankyrin 1 ion channel in the inflamed human and mouse colon and its protective roles. PLoS One 9(9):e108164CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173CrossRefPubMedPubMedCentral Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173CrossRefPubMedPubMedCentral
24.
25.
Zurück zum Zitat Lembeck F, Donnerer J (2004) History of a pioneering neuropeptide: substance P. Tachykinins:1–23 Lembeck F, Donnerer J (2004) History of a pioneering neuropeptide: substance P. Tachykinins:1–23
26.
Zurück zum Zitat Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245(18):4784–4790PubMed Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245(18):4784–4790PubMed
27.
Zurück zum Zitat Gasparovic I, Hadzovic S, Hukovic S, Stern P (1964) Contribution to the theory that substance P has a transmitter role in sensitive pathway. Med Exp Int J Exp Med 10:303–306PubMed Gasparovic I, Hadzovic S, Hukovic S, Stern P (1964) Contribution to the theory that substance P has a transmitter role in sensitive pathway. Med Exp Int J Exp Med 10:303–306PubMed
28.
Zurück zum Zitat Jessell TM, Iversen LL, Cuello AC (1978) Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res 152(1):183–188CrossRefPubMed Jessell TM, Iversen LL, Cuello AC (1978) Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res 152(1):183–188CrossRefPubMed
29.
Zurück zum Zitat Hokfelt T, Kellerth JO, Nilsson G, Pernow B (1975) Substance p: localization in the central nervous system and in some primary sensory neurons. Science 190(4217):889–890CrossRefPubMed Hokfelt T, Kellerth JO, Nilsson G, Pernow B (1975) Substance p: localization in the central nervous system and in some primary sensory neurons. Science 190(4217):889–890CrossRefPubMed
30.
Zurück zum Zitat Gamse R, Holzer P, Lembeck F (1980) Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol 68(2):207–213CrossRefPubMedPubMedCentral Gamse R, Holzer P, Lembeck F (1980) Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol 68(2):207–213CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lembeck F, Donnerer J (1981) Postocclusive cutaneous vasodilatation mediated by substance P. Naunyn Schmiedebergs Arch Pharmacol 316(2):165–171CrossRefPubMed Lembeck F, Donnerer J (1981) Postocclusive cutaneous vasodilatation mediated by substance P. Naunyn Schmiedebergs Arch Pharmacol 316(2):165–171CrossRefPubMed
32.
Zurück zum Zitat Lembeck F, Holzer P (1979) Substance-P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310(2):175–183CrossRefPubMed Lembeck F, Holzer P (1979) Substance-P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310(2):175–183CrossRefPubMed
33.
Zurück zum Zitat Lembeck F (1983) Sir Thomas Lewis’s nocifensor system, histamine and substance-P-containing primary afferent nerves. Trends Neurosci 6:106–108CrossRef Lembeck F (1983) Sir Thomas Lewis’s nocifensor system, histamine and substance-P-containing primary afferent nerves. Trends Neurosci 6:106–108CrossRef
34.
Zurück zum Zitat Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 87(4):533–536CrossRefPubMed Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 87(4):533–536CrossRefPubMed
35.
Zurück zum Zitat Erspamer V (1981) The tachykinin peptide family. Trends Neurosci 4:267–269CrossRef Erspamer V (1981) The tachykinin peptide family. Trends Neurosci 4:267–269CrossRef
36.
37.
Zurück zum Zitat Hill R (2000) NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends Pharmacol Sci 21(7):244–246CrossRefPubMed Hill R (2000) NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends Pharmacol Sci 21(7):244–246CrossRefPubMed
38.
Zurück zum Zitat Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR (2017) Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer 17(1):200CrossRefPubMedPubMedCentral Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR (2017) Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer 17(1):200CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Lotts T, Stander S (2014) Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges 12(7):557–559PubMed Lotts T, Stander S (2014) Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges 12(7):557–559PubMed
40.
Zurück zum Zitat Atoyan R, Shander D, Botchkareva NV (2009) Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J Invest Dermatol 129(9):2312–2315CrossRefPubMed Atoyan R, Shander D, Botchkareva NV (2009) Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J Invest Dermatol 129(9):2312–2315CrossRefPubMed
41.
Zurück zum Zitat Lundberg JM, Franco-Cereceda A, Hua X, Hokfelt T, Fischer JA (1985) Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol 108(3):315–319CrossRefPubMed Lundberg JM, Franco-Cereceda A, Hua X, Hokfelt T, Fischer JA (1985) Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol 108(3):315–319CrossRefPubMed
42.
Zurück zum Zitat Gibbins IL, Furness JB, Costa M, MacIntyre I, Hillyard CJ, Girgis S (1985) Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. Neurosci Lett 57(2):125–130CrossRefPubMed Gibbins IL, Furness JB, Costa M, MacIntyre I, Hillyard CJ, Girgis S (1985) Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. Neurosci Lett 57(2):125–130CrossRefPubMed
43.
Zurück zum Zitat Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313(5997):54–56CrossRefPubMed Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313(5997):54–56CrossRefPubMed
44.
Zurück zum Zitat McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83(15):5731–5735CrossRefPubMedPubMedCentral McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83(15):5731–5735CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2):193–196CrossRefPubMed Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2):193–196CrossRefPubMed
46.
Zurück zum Zitat Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron PM (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A 88(22):10208–10212CrossRefPubMedPubMedCentral Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron PM (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A 88(22):10208–10212CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393(6683):333–339CrossRefPubMed McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393(6683):333–339CrossRefPubMed
48.
Zurück zum Zitat Chapman LF (1977) Mechanisms of the flare reaction in human skin. J Invest Dermatol 69(1):88–97CrossRefPubMed Chapman LF (1977) Mechanisms of the flare reaction in human skin. J Invest Dermatol 69(1):88–97CrossRefPubMed
49.
Zurück zum Zitat Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR, de Hoon JN (2008) Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 325(1):248–255CrossRefPubMed Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR, de Hoon JN (2008) Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 325(1):248–255CrossRefPubMed
50.
Zurück zum Zitat Escott KJ, Brain SD (1993) Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br J Pharmacol 110(2):772–776CrossRefPubMedPubMedCentral Escott KJ, Brain SD (1993) Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br J Pharmacol 110(2):772–776CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Murota H, Katayama I (2016) Evolving understanding on the aetiology of thermally provoked itch. Eur J Pain 20(1):47–50CrossRefPubMed Murota H, Katayama I (2016) Evolving understanding on the aetiology of thermally provoked itch. Eur J Pain 20(1):47–50CrossRefPubMed
52.
53.
Zurück zum Zitat Smillie SJ, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45(2):93–104CrossRefPubMed Smillie SJ, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45(2):93–104CrossRefPubMed
54.
Zurück zum Zitat Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153(6):1105–1119CrossRefPubMed Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153(6):1105–1119CrossRefPubMed
55.
Zurück zum Zitat Opitz CF, Ewert R (2006) Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest 36(Suppl 3):1–9CrossRefPubMed Opitz CF, Ewert R (2006) Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest 36(Suppl 3):1–9CrossRefPubMed
56.
Zurück zum Zitat Gamse R, Lackner D, Gamse G, Leeman SE (1981) Effect of capsaicin pretreatment on capsaicin-evoked release of immunoreactive somatostatin and substance P from primary sensory neurons. Naunyn-Schmiedeberg’s Arch Pharmacol 316(1):38–41CrossRef Gamse R, Lackner D, Gamse G, Leeman SE (1981) Effect of capsaicin pretreatment on capsaicin-evoked release of immunoreactive somatostatin and substance P from primary sensory neurons. Naunyn-Schmiedeberg’s Arch Pharmacol 316(1):38–41CrossRef
57.
Zurück zum Zitat Szolcsanyi J, Pinter E, Helyes Z, Petho G (2011) Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Top Med Chem 11(17):2253–2263CrossRefPubMed Szolcsanyi J, Pinter E, Helyes Z, Petho G (2011) Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Top Med Chem 11(17):2253–2263CrossRefPubMed
59.
Zurück zum Zitat Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389(6653):816–824CrossRefPubMed Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389(6653):816–824CrossRefPubMed
60.
Zurück zum Zitat Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288(5464):306–313CrossRefPubMed Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288(5464):306–313CrossRefPubMed
61.
Zurück zum Zitat Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405(6783):183–187CrossRefPubMed Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405(6783):183–187CrossRefPubMed
62.
Zurück zum Zitat Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819–829CrossRefPubMed Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819–829CrossRefPubMed
63.
Zurück zum Zitat Andersson DA, Gentry C, Moss S, Bevan S (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 28(10):2485–2494CrossRefPubMedPubMedCentral Andersson DA, Gentry C, Moss S, Bevan S (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 28(10):2485–2494CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Eberhardt M, Dux M, Namer B, Miljkovic J, Cordasic N, Will C, Kichko TI, de la Roche J, Fischer M, Suarez SA, Bikiel D, Dorsch K, Leffler A, Babes A, Lampert A, Lennerz JK, Jacobi J, Marti MA, Doctorovich F, Hogestatt ED, Zygmunt PM, Ivanovic-Burmazovic I, Messlinger K, Reeh P, Filipovic MR (2014) H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nat Commun 5:4381CrossRefPubMed Eberhardt M, Dux M, Namer B, Miljkovic J, Cordasic N, Will C, Kichko TI, de la Roche J, Fischer M, Suarez SA, Bikiel D, Dorsch K, Leffler A, Babes A, Lampert A, Lennerz JK, Jacobi J, Marti MA, Doctorovich F, Hogestatt ED, Zygmunt PM, Ivanovic-Burmazovic I, Messlinger K, Reeh P, Filipovic MR (2014) H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nat Commun 5:4381CrossRefPubMed
65.
Zurück zum Zitat Aubdool AA, Graepel R, Kodji X, Alawi KM, Bodkin JV, Srivastava S, Gentry C, Heads R, Grant AD, Fernandes ES, Bevan S, Brain SD (2014) TRPA1 is essential for the vascular response to environmental cold exposure. Nat Commun 5:5732CrossRefPubMed Aubdool AA, Graepel R, Kodji X, Alawi KM, Bodkin JV, Srivastava S, Gentry C, Heads R, Grant AD, Fernandes ES, Bevan S, Brain SD (2014) TRPA1 is essential for the vascular response to environmental cold exposure. Nat Commun 5:5732CrossRefPubMed
66.
Zurück zum Zitat Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD (2005) Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum 52(10):3248–3256CrossRefPubMed Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD (2005) Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum 52(10):3248–3256CrossRefPubMed
67.
Zurück zum Zitat Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R, Gentry C, Staniland AA, Mountford DM, Keeble JE, Malcangio M, Bevan S, Brain SD (2011) A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and Freund’s complete adjuvant-induced monarthritis. Arthritis Rheum 63(3):819–829CrossRefPubMed Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R, Gentry C, Staniland AA, Mountford DM, Keeble JE, Malcangio M, Bevan S, Brain SD (2011) A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and Freund’s complete adjuvant-induced monarthritis. Arthritis Rheum 63(3):819–829CrossRefPubMed
68.
Zurück zum Zitat Gavva NR, Bannon AW, Surapaneni S, Hovland DN Jr, Lehto SG, Gore A, Juan T, Deng H, Han B, Klionsky L, Kuang R, Le A, Tamir R, Wang J, Youngblood B, Zhu D, Norman MH, Magal E, Treanor JJ, Louis JC (2007) The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 27(13):3366–3374CrossRefPubMedPubMedCentral Gavva NR, Bannon AW, Surapaneni S, Hovland DN Jr, Lehto SG, Gore A, Juan T, Deng H, Han B, Klionsky L, Kuang R, Le A, Tamir R, Wang J, Youngblood B, Zhu D, Norman MH, Magal E, Treanor JJ, Louis JC (2007) The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 27(13):3366–3374CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat Preti D, Saponaro G, Szallasi A (2015) Transient receptor potential ankyrin 1 (TRPA1) antagonists. Pharm Pat Anal 4(2):75–94CrossRefPubMed Preti D, Saponaro G, Szallasi A (2015) Transient receptor potential ankyrin 1 (TRPA1) antagonists. Pharm Pat Anal 4(2):75–94CrossRefPubMed
71.
Zurück zum Zitat Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P (2001) Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357(9265):1338–1339CrossRefPubMed Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P (2001) Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357(9265):1338–1339CrossRefPubMed
72.
Zurück zum Zitat Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, Story GM, Colley S, Hogenesch JB, McIntyre P, Bevan S, Patapoutian A (2002) A heat-sensitive TRP channel expressed in keratinocytes. Science 296(5575):2046–2049CrossRefPubMed Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, Story GM, Colley S, Hogenesch JB, McIntyre P, Bevan S, Patapoutian A (2002) A heat-sensitive TRP channel expressed in keratinocytes. Science 296(5575):2046–2049CrossRefPubMed
73.
Zurück zum Zitat Zimmermann K, Leffler A, Fischer MM, Messlinger K, Nau C, Reeh PW (2005) The TRPV1/2/3 activator 2-aminoethoxydiphenyl borate sensitizes native nociceptive neurons to heat in wildtype but not TRPV1 deficient mice. Neuroscience 135(4):1277–1284CrossRefPubMed Zimmermann K, Leffler A, Fischer MM, Messlinger K, Nau C, Reeh PW (2005) The TRPV1/2/3 activator 2-aminoethoxydiphenyl borate sensitizes native nociceptive neurons to heat in wildtype but not TRPV1 deficient mice. Neuroscience 135(4):1277–1284CrossRefPubMed
74.
Zurück zum Zitat Kimball ES, Prouty SP, Pavlick KP, Wallace NH, Schneider CR, Hornby PJ (2007) Stimulation of neuronal receptors, neuropeptides and cytokines during experimental oil of mustard colitis. Neurogastroenterol Motil 19(5):390–400CrossRefPubMed Kimball ES, Prouty SP, Pavlick KP, Wallace NH, Schneider CR, Hornby PJ (2007) Stimulation of neuronal receptors, neuropeptides and cytokines during experimental oil of mustard colitis. Neurogastroenterol Motil 19(5):390–400CrossRefPubMed
75.
Zurück zum Zitat Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, Heller S (2000) Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 103(3):525–535CrossRefPubMedPubMedCentral Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, Heller S (2000) Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 103(3):525–535CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Vergnolle N, Cenac N, Altier C, Cellars L, Chapman K, Zamponi GW, Materazzi S, Nassini R, Liedtke W, Cattaruzza F, Grady EF, Geppetti P, Bunnett NW (2010) A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation. Br J Pharmacol 159(5):1161–1173CrossRefPubMedPubMedCentral Vergnolle N, Cenac N, Altier C, Cellars L, Chapman K, Zamponi GW, Materazzi S, Nassini R, Liedtke W, Cattaruzza F, Grady EF, Geppetti P, Bunnett NW (2010) A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation. Br J Pharmacol 159(5):1161–1173CrossRefPubMedPubMedCentral
77.
Zurück zum Zitat McKemy DD, Neuhausser WM, Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416(6876):52–58CrossRefPubMed McKemy DD, Neuhausser WM, Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416(6876):52–58CrossRefPubMed
78.
Zurück zum Zitat Olsen RV, Andersen HH, Moller HG, Eskelund PW, Arendt-Nielsen L (2014) Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers. Eur J Pain 18(9):1333–1342CrossRefPubMed Olsen RV, Andersen HH, Moller HG, Eskelund PW, Arendt-Nielsen L (2014) Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers. Eur J Pain 18(9):1333–1342CrossRefPubMed
79.
Zurück zum Zitat Vriens J, Owsianik G, Hofmann T, Philipp SE, Stab J, Chen X, Benoit M, Xue F, Janssens A, Kerselaers S, Oberwinkler J, Vennekens R, Gudermann T, Nilius B, Voets T (2011) TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron 70(3):482–494CrossRefPubMed Vriens J, Owsianik G, Hofmann T, Philipp SE, Stab J, Chen X, Benoit M, Xue F, Janssens A, Kerselaers S, Oberwinkler J, Vennekens R, Gudermann T, Nilius B, Voets T (2011) TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron 70(3):482–494CrossRefPubMed
80.
Zurück zum Zitat Held K, Kichko T, De Clercq K, Klaassen H, Van Bree R, Vanherck JC, Marchand A, Reeh PW, Chaltin P, Voets T, Vriens J (2015) Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release. Proc Natl Acad Sci U S A 112(11):E1363–E1372CrossRefPubMedPubMedCentral Held K, Kichko T, De Clercq K, Klaassen H, Van Bree R, Vanherck JC, Marchand A, Reeh PW, Chaltin P, Voets T, Vriens J (2015) Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release. Proc Natl Acad Sci U S A 112(11):E1363–E1372CrossRefPubMedPubMedCentral
81.
Zurück zum Zitat von Euler US, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72(1):74–87CrossRef von Euler US, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72(1):74–87CrossRef
82.
Zurück zum Zitat Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304(5922):129–135CrossRefPubMed Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304(5922):129–135CrossRefPubMed
83.
Zurück zum Zitat Masu Y, Nakayama K, Tamaki H, Harada Y, Kuno M, Nakanishi S (1987) cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature 329(6142):836–838CrossRefPubMed Masu Y, Nakayama K, Tamaki H, Harada Y, Kuno M, Nakanishi S (1987) cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature 329(6142):836–838CrossRefPubMed
84.
Zurück zum Zitat Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, Group BBCPoCS (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11):1104–1110CrossRefPubMed Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, Group BBCPoCS (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11):1104–1110CrossRefPubMed
85.
Zurück zum Zitat Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, investigators ALDs (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100–1107CrossRefPubMed Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, investigators ALDs (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100–1107CrossRefPubMed
86.
Zurück zum Zitat Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885–892CrossRefPubMed Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885–892CrossRefPubMed
87.
Zurück zum Zitat Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081–1090CrossRefPubMed Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081–1090CrossRefPubMed
88.
Zurück zum Zitat Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390CrossRefPubMed Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390CrossRefPubMed
Metadaten
Titel
A historical perspective on the role of sensory nerves in neurogenic inflammation
Publikationsdatum
03.04.2018
Erschienen in
Seminars in Immunopathology / Ausgabe 3/2018
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-018-0673-1

Weitere Artikel der Ausgabe 3/2018

Seminars in Immunopathology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.